Business Wire

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference


CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolio during the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.

“We look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,” said Reg Seeto, CEO and President of CareDx. “We are committed to advancing the field of immunogenetics and histocompatibility and take great pride in supporting this important event as a platinum sponsor.”

CareDx will be on hand to display its leadership in serving European laboratories, researchers, and clinicians with its best-in-class product portfolio of next-generation sequencing (NGS) based AlloSeq* products, which enables best-in-class care both pre- and post-transplantation.

For pre-transplant, CareDx offers AlloSeq Tx* HLA typing solutions. For post-transplant, CareDx offers AlloSeq HCT* chimerism testing and AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively. CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.

CareDx will sponsor a symposium “Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes” on Thursday, April 27. The event will be moderated by Curtis Lind, CareDx Vice President and Head of R&D products. Panelists and topics include:

  • Monica Irina Dutescu M,D., Ph.D. , National HLA Laboratory, National Institute of Blood Transfusion Prof. Dr. C.T. NICOLAU Bucharest, Romania: High Resolution HLA Typing with AlloSeq Tx – the Experience of National HLA Laboratory, Bucharest.
  • Miguel Alcoceba Ph.D. , Department of Haematology, University Hospital of Salamanca (HUS-IBSAL) Salamanca, Spain: Comparison of Next-Generation Sequencing and Short-Tandem Repeats to Monitor Chimerism Analysis.
  • Olivier Aubert M.D., Ph.D. , Necker-Enfants Malades Hospital - Paris Transplant Group, Paris, France: dd-cfDNA in Allograft Rejection and Risk Assessment.

“I look forward to participating in the CareDx sponsored symposium and showing how its innovative HLA typing solutions represent a strong, efficient, and user-friendly technique for pre-transplant testing, that provides reliable, accurate results. I will also demonstrate how the use of its hybrid capture method can also provide the best coverage, high level of transplant matching and low rates of ambiguity in one product,” said Monica Irina Dutescu, M.D., Ph.D., National Institute of Blood Transfusion, Bucharest.

The following nine AlloSeq* oral presentations and posters will be presented at the meeting.


First Author


Featuring AlloSeq Tx17 and Hybrid Capture

The expanded role of microRNAs in controlling the HLA class I phenotype: Relationship between the 3’ UTR and post-transcriptional Gene Regulation

Panagiotis Mallis


Detection of HLA-A and HLA-J haplotype diversity from next-generation sequencing data in commercially available samples.

Jessica Edwards


Identification of the novel HLA-DPB1*02:01:68 allele in a Greek individual

Diamanto Kouniaki


Identification of the novel HLA-A*01:426 allele in a Greek individual

Diamanto Kouniaki


Identification of the novel HLA-A*02:09:01:04 allele in a Greek individual

Diamanto Kouniaki


Featuring AlloSeq HCT

Evaluation of the Magelia for automated purification of CareDx AlloSeq HCT kit libraries in the context of post-hematopoietic stem cells transplantation chimerism assessment

Coralie Frassati


Featuring AlloSeq cfDNA Assay and Software

Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation

Pascal Pedini


Donor specific HLA-DPw antibodies in a highly sensitized kidney transplant recipient – a case report

Dolores Hrusovar


Results of the 6 Months Post-Transplant Surveillance in patients transplanted with preformed donor-specific anti-HLA antibodies (DSA) by Adding Donor-Derived Cell-Free DNA Testing

María Lasa-Lázaro


*AlloSeq Tx, AlloSeq HCT and AlloSeq cfDNA are available as CE/IVD in the EU and in the U.K., and Research Use Only for the rest of the world. AlloSeq Service is available as Research Use Only. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is only available outside of the United States. For local regulatory status, please contact CareDx.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit:

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s AlloSeq* portfolio of lab products, as well as CareDx’s leading participation at the 36th European Immunogenetics and Histocompatibility Conference (the “Participation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq* portfolio or Participation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

To view this piece of content from, please give your consent at the top of this page.

Contact information

CareDx, Inc.
Media Relations
Anna Czene

Investor Relations
Greg Chodaczek

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com

The Podium Welcomes the Conquerors of 2023 Taklimakan Rally!2.6.2023 04:33:00 EEST | Press release

Among the 97 autos and 37 motorcycles who have started the Rally in Aksu on May 20, 76 autos and 31 motos have successfully withstood the tough challenges and reached the finish line. This press release features multimedia. View the full release here: As the 15th edition of Taklimakan Rally, the 2023 Taklimakan Rally lasts for 13 days. The 4258 km total stage contains 1 SSS, 9 stages and 2 rest days. The rally sets foot in the south west of Xinjiang and covers 3 regions of Aksu, Kashgar and Hotan. The multi-terrain stages together with the beautiful scenery has attracted 231 competitors from China and abroad to participate. In the auto category, the final victory goes to Zi Yungang/Wang Zengrong from Shanxi Yunxiang Team. Team BAIC contributes to the podium with Zhang Guoyu/Oriol Mena Valdearcos and Liu Yangui/Chen Feng listed the 2nd and 3rd place. As to the moto, Bradley John Cox and Arunas Gelazninkas continued their good per

UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release

More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati

Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France1.6.2023 19:30:00 EEST | Press release

Regulatory News: This press release features multimedia. View the full release here: Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France Carbios (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, and Indorama Ventures Public Company Limited (IVL) (Bloomberg ticker IVL.TB), a global sustainable chemical producer, announce today the signing of a non-binding Memorandum of Understanding (MOU) to form a Joint Venture for the construction of the world’s first PET biorecycling plant in France1. Based on and subject to the comprehensive terms set out in the MOU, Indorama Ventures plans to mobilize about €110 million for the Joint Venture in equity and non-convertible loan financing2, pending final engineering documentation and final economic feasibility studies. Both parties have

PPG opens Color Creation Lab with Chery Automobile in China1.6.2023 16:01:00 EEST | Press release

PPG (NYSE:PPG) today announced the opening of a Color Creation Lab in collaboration with automaker Chery Automobile Co., Ltd. At the facility, located in Wuhu, China, PPG color stylists and Chery designers will create new colors tailored to specific vehicle designs, from initial color recommendations to final materials for application in Chery’s manufacturing plants. This press release features multimedia. View the full release here: Representatives from PPG and Chery Automobile celebrate the opening of a Color Creation Lab in Wuhu, China. (Photo: PPG) “As the leading single-source coatings supplier for automotive manufacturing, PPG is excited to partner with Chery, a company that prioritizes technological innovation and sustainable production,” said Thomas Li, PPG vice president Asia Pacific, Automotive Coatings. “We will leverage our global color leadership to predict future trends, while advancing paint technology for the nex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom